NCT03791567View on ClinicalTrials.gov

Islet Transplantation in Type I Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol

APPROVED_FOR_MARKETINGEXPANDED_ACCESS

Timeline

Start Date

Not specified

Conditions

Type 1 Diabetes Mellitus

Interventions

BIOLOGICAL

Donislecel (allogeneic islets of Langerhans for transplant)

Intervention Description: The drug product consists of allogeneic human islets of Langerhans (islets) in serum-free transplant medium (indicator-free CMRL 1066 medium with HEPES, without sodium bicarbonate and supplemented with human albumin).

Trial Locations (1)

60612

University of Illinois at Chicago Medical Center, Chicago